Page 349 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 349

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
 surveillance/ watchful waiting/other observational management strategies (continued)

 Center, Country   Eligibility criteria   Followup or monitoring protocol   Triggers for intervention/   Definition of
 [PMID]                          active therapy                   progression
 Enrollment year
 measured by
 planimetric
 calculation
 during TRUS.
 After a PCA
 diagnosis, men
 are referred to
 the regular
 medical circuit
 (which may be
 the ERSPC
 centre), where
 decisions on
 treatment are
 made. 151
 Four tertiary care   Patients who   Office visits, review of general health and urinary symptoms,   Criteria for recommending   NR
 academic medical   would otherwise   DRE and PSA every 6 to 12 mo, rebiopsies within 18 mo of   treatment were
 m
 canters,  US 109    be considered   starting AS and subsequently every 1 to 3 yr or prompted by a   nonstandardized and
 [19233410]   for surgery or   change in clinical status (e.g., significant and sustained PSA   physician specific.
    radiation due to   increase). MRI of the prostate was selectively used at
 1991-2007   a life   diagnosis and every 1 to 3 yr after starting AS.
 expectancy >10
 yr, and were
 defined as age
 ≤75 yr, clinical
 stage T1-T2a,
 PSA ≤10
 ng/mL, ≤3
 positive cores
 at diagnostic
 biopsy, Gleason
 score ≤6, no
 active treatment
 for a minimum
 of 6 mo after
 the second
 biopsy.







 C-92
   344   345   346   347   348   349   350   351   352   353   354